By Matthew DellaBetta and Ryan K. Stumphauzer – former federal prosecutors · Stumphauzer Kolaya & Sloman, PLLC · June 26, 2026
On June 25, 2026, the Department of Justice (“DOJ”) announced the results of its 2026 National Health Care Fraud Takedown—and the numbers reset the baseline for what federal enforcement looks like. Prosecutors charged 455 defendants, including 90 doctors and other licensed medical professionals, in schemes involving more than $6.5 billion in alleged false claims. The cases reach across 56 federal districts and 45 states and territories, with 50 state Medicaid Fraud Control Units participating—the most in the Department’s history.[1]
| 455 defendants charged, incl. 90 licensed professionals | $6.5B+ in alleged false claims |
| $182M+ in cash and assets seized | 56 federal districts involved |
It would be easy to read those figures as a story about fraudsters getting caught. Indeed, the DOJ’s press release highlights the seizure of more than $182 million in cash, luxury vehicles, jewelry, and other assets from some defendants. The more important story—the one every legitimate provider, lab, and practice manager should be paying attention to—is how the government got there.
Enforcement is now data-driven and focused on pre-payment
The defining feature of this takedown is not its size. It is the method. The DOJ and the Centers for Medicare & Medicaid Services (CMS) emphasized the “cutting-edge use of data analytics to target the worst actors” and a shift toward stopping payments before money goes out the door. CMS suspended 1,079 providers and revoked the billing privileges of 1,403 more, and the government seized over $182 million in cash, vehicles, and other assets in what one U.S. Attorney described as a “follow and seize the money” approach.[2]
Here is why that matters for honest providers: algorithms do not distinguish between fraud and an unusual-but-legitimate billing pattern. They flag outliers. A solo specialist with a high volume of a particular code, a lab whose ordering physicians cluster geographically, a DME supplier whose claims spiked after a marketing push—each can look, statistically, like the cases DOJ just charged. When the Government leads with data, the burden of explanation effectively shifts to the provider.
Skin substitutes and wound care: the highest-risk category right now
The charged conduct concentrated in several fields that DOJ has consistently targeted: durable medical equipment (DME), laboratory and genetic testing, telemedicine, community mental health and psychosocial rehabilitation services, and opioid prescribing. But If there is one corner of health care to watch, it is skin substitutes and wound care. The 2026 Takedown leaned hard into this space. In the Southern District of Florida alone, prosecutors charged a defendant who allegedly set up at least eleven clinics that billed Medicare more than $117 million for skin substitutes and wound-care products that were never provided and the Government seized more than $27 million from a dozen “bust-out” clinics that had billed for amniotic wound allografts and services never rendered.
The reason this category draws such intense scrutiny is structural: these grafts carry high per-unit reimbursement, billing volume has grown rapidly, and that combination is precisely what the Government’s claims-data algorithms are built to flag. The practical risk is that legitimate wound-care providers, such as those genuinely treating diabetic ulcers and chronic non-healing wounds, can land in the same data set as the fraud cases, and be asked to prove the difference. If you bill for skin substitutes, now is the time to make sure your medical-necessity documentation, your supplier relationships, and your marketing arrangements would withstand a government audit.
Setting aside the numbers and defending against these complex cases
For all the weight of a multi-count indictment, health care fraud cases are far more defensible than the headline numbers suggest, because the Government must prove what was in the defendant’s mind. The federal health care fraud and anti-kickback statutes require that conduct be “knowing and willful” — so the fight is often not over what was billed, but over intent. A strong defense frequently begins there: showing that a provider relied in good faith on professional coders, billing companies, or compliance advice; that an arrangement had a legitimate medical or business purpose; or that judgment calls on medical necessity reflected accepted clinical practice rather than fraud. Just as often, the defense attacks the Government’s method.
Because these prosecutions increasingly rest on statistical extrapolation from claims data, the sampling methodology, the assumptions behind it, and the leap from “billing outlier” to “criminal” are all fair targets — and an outlier with a sound explanation is not a crime. Where the alleged loss figure drives the sentencing exposure, contesting that number (including credit for services that were rendered and legitimately reimbursable) can matter as much as the verdict itself. And the most valuable work often happens before any of that, in the investigative stage, when a well-supported presentation to prosecutors — documentation, context, an alternative narrative the agents never had — can narrow the charges or end the matter entirely.
[1]U.S. Department of Justice, Office of Public Affairs, “National Health Care Fraud Takedown Results in 455 Defendants Charged in Connection with Over $6.5 Billion in Alleged Fraud” (June 25, 2026). https://www.justice.gov/opa/pr/national-health-care-fraud-takedown-results-455-defendants-charged-connection-over-65
